Peled Amnon 4

4 · Silexion Therapeutics Corp · Filed Feb 23, 2026

AI-generated summary of this filing

Updated Feb 23, 2026

Silexion (SLXN) Director Amnon Peled Receives RSUs & Options

What Happened

Amnon Peled, a director of Silexion Therapeutics Corp (SLXN), received two grants on Feb 20, 2026: 7,576 fully vested restricted share units (RSUs) that were immediately settled for ordinary shares, and a separate grant of options covering 8,904 ordinary shares. Both grants show an acquisition price of $0.00 (standard for equity awards); the RSUs were settled into shares immediately, and the options are a derivative grant.

Key Details

Transaction date: 2026-02-20; Form 4 filed 2026-02-23 (timely filing).
RSU grant: 7,576 ordinary shares acquired at $0.00; settled immediately into shares (footnote F1).
Option grant: options to purchase 8,904 ordinary shares at $0.00 reported as a derivative grant (footnotes F2–F3).
Option terms: vest in full on the one-year anniversary of grant and expire ten years after grant approval (F3).
Board approval: both grants were approved by Silexion’s board of directors (F1, F2).
Shares owned after transaction: not specified in the provided filing excerpt (F4 notes certain rows included for informational purposes).

Context

These were compensation grants (awards), not open-market purchases or sales — they represent director compensation rather than a direct market bet. The RSUs were settled immediately into shares; the options are subject to a one-year cliff vesting and long (10-year) term before expiration. No cash changed hands at grant.

Form 4

Period: 2026-02-20

Director

Transactions

Award
Ordinary Shares
[F1]
2026-02-20+7,576→ 8,237 total
Award
Stock Option (right to buy Ordinary Shares)
[F2][F3]
2026-02-20+8,904→ 8,904 total
Exercise: $1.65From: 2027-02-12Exp: 2036-02-12→ Ordinary Shares (8,904 underlying)

Holdings

Stock Option (right to buy Ordinary Shares)
[F4]
Exercise: $18.90From: 2026-02-09Exp: 2035-02-09→ Ordinary Shares (780 underlying)
780

Footnotes (4)

[F1]The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, par value $0.0135 per share, of the Issuer ("ordinary shares"), in respect of the Reporting Person's director services to the Issuer. The grant was approved by the Issuer's board of directors.
[F2]The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of options to purchase ordinary shares, which grant was approved by the Issuer's board of directors.
[F3]The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors.
[F4]There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.

Signature

/s/ Mirit Horenshtein Hadar, Attorney-in-fact|2026-02-23

2 files